Bioventus (BVS) Receivables - Net (2020 - 2026)

Bioventus (BVS) has reported Receivables - Net for 7 consecutive years, with $141.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 4.25% year-over-year to $141.0 million; the trailing twelve-month figure through Jun 2026 stood at $141.0 million (up 4.25% YoY), and the FY2025 full-year result was $131.2 million, up 0.73% from the prior year.
• Receivables - Net rose to $141.0 million in Q2 2026 per BVS's latest filing, from $120.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $148.3 million in Q3 2022 and bottomed at $117.9 million in Q3 2023.
• Historically, Receivables - Net has averaged $130.9 million across 5 years, with a median of $129.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net surged 41.18% in 2022, then dropped 14.56% in 2023.
• Over 5 years, Receivables - Net stood at $143.3 million in 2022, then fell by 11.38% to $127.0 million in 2023, then rose by 2.56% to $130.3 million in 2024, then advanced by 0.73% to $131.2 million in 2025, then rose by 7.48% to $141.0 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $141.0 million, $120.5 million, and $131.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.